Investigational drug · Phase 2
UCB0022
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Parkinson Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
4
Any phase or sponsor naming "UCB0022"
First trial start
2023
Nov 17, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "UCB0022", any sponsor or status.
Conditions studied
As listed on its trial records.
- Parkinson Disease
Approved drugs for the same conditions: Parkinson's disease · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "UCB0022" as an intervention, largest first.
- A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's DiseasePivotal-lookingCompleted
NCT06055985 · 207 participants · Start Nov 17, 2023 · Primary completion Mar 31, 2025
Drug: UCB0022 · For: Parkinson Disease
Sites: Phoenix, Arizona; Scottsdale, Arizona; Little Rock, Arkansas · 61 sites in all
- A Study to Test the Safety, Tolerability, and Blood Levels of UCB0022 in Healthy Participants and Participants With Parkinson's DiseasePivotal-lookingCompleted
NCT04867642 · 100 participants · Start Apr 29, 2021 · Primary completion Feb 27, 2023
Drug: UCB0022 · For: Healthy Study Participants; Parkinson's Disease
Sites: London, United Kingdom
NCT06970301 · 32 participants · Start Apr 28, 2025 · Primary completion May 29, 2026
Drug: glovadalen · For: Healthy Study Participants
Sites: Glendale, California
NCT07220551 · 14 participants · Start Oct 23, 2025 · Primary completion Dec 16, 2025
Drug: UCB0022 · For: Healthy Volunteers
Sites: San Antonio, Texas
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Parkinson Disease
- RadotinibSupect, IY5511Phase 33 trials
Il-Yang Pharm. Co., Ltd. · Chronic Myeloid Leukemia, Chronic Phase, CML, Chronic Phase, CML, Refractory
- CVN424Phase 32 trials
Cerevance · Parkinson Disease, Parkinson's Disease
- BHV-8000Phase 31 trial
Biohaven Therapeutics Ltd. · Parkinson Disease
- Human Dopaminergic Progenitor CellsNouvNeu001Phase 23 trials
iRegene Therapeutics Co., Ltd. · Parkinson Disease, Parkinson Disease (PD)
- AB-1005Phase 22 trials
AskBio Inc · PARKINSON DISEASE (Disorder), Parkinson Disease
- DNL151BIIB122Phase 22 trials
Denali Therapeutics Inc. · Parkinson Disease
- HBI-002Phase 22 trials
Hillhurst Biopharmaceuticals, Inc. · Parkinson Disease, Anemia, Sickle Cell
- VutiglabridinHSG4112Phase 22 trials
Glaceum · Knee Osteoarthritis (Knee OA), Parkinson Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from UCB.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.